11 Best Penny Stocks to Invest in Under $1

Page 10 of 10

1. Gossamer Bio Inc. (NASDAQ:GOSS)

Share Price as of April 10: $0.88

Number of Hedge Fund Holders: 35

Gossamer Bio Inc. (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company that develops and commercializes seralutinib for the treatment of pulmonary arterial hypertension (PAH). It’s developing GB002, which is an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, and c-KIT inhibitor.

The company is currently conducting a Phase 3 clinical trial called the PROSERA Study for PAH patients, which assesses the change in six-minute walk distance from baseline at week 24, with topline results expected in Q4 2025. The company has also received Orphan Drug Designation for seralutinib in Japan. This could lead to a marketing application in Japan if the PROSERA study is successful.

In addition to PAH, Gossamer Bio Inc. (NASDAQ:GOSS) plans to initiate a Phase 3 clinical trial for PH-ILD patients in H2 2025. The company reported $294.5 million in cash, cash equivalents, and marketable securities for the full year 2024. This amount will be sufficient to fund operations for Gossamer Bio Inc. (NASDAQ:GOSS) into H1 2027.

While we acknowledge the growth potential of Gossamer Bio Inc. (NASDAQ:GOSS), our conviction lies in the belief that AI stocks hold great promise for delivering high returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than GOSS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 10 of 10